Changsha Pharmaceutical Company Zhongsheng Quanpeptide Plans IPO: R&D Investment of 600 Million Yuan Over Next 3 Years, Secures Orders from AstraZeneca

NightAirdropper · 2026-03-18T00:27:38+00:00

Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd. completed IPO counseling and filing. The company specializes in the research and development of polypeptide-based therapeutic drugs. Founded in 2017, the company has dispersed equity with the founding team collectively controlling 50.87% of shares. The company has completed multiple rounds of financing with nearly 400 million yuan in cumulative R&D investment. It plans to invest an additional 600 million yuan in R&D over the next three years.

NightAirdropper

2026-03-18 00:27:38

Abstract generation in progress

Rui Finance Yanminghui Recently, Hunan Zhongsheng Quantai Biotechnology Co., Ltd. (hereinafter referred to as:) completed IPO counseling filing with the Hunan Securities Regulatory Bureau, with Shenwan Hongyuan Securities as the counseling institution.

Zhongsheng Quantai was established in September 2017, with a registered capital of 52.172 million yuan. It is an innovative biotechnology company dedicated to discovering and developing new peptide-based therapeutic drugs. The company is headquartered in Zhuzhou, China, with subsidiaries in Changsha and New Jersey, USA.

Zhongsheng Quantai has dispersed ownership, with no single shareholder holding more than 30%, and no controlling shareholder.

Chairman Chen Lei directly holds 20.56% of shares and indirectly holds 1.48%; General Manager Li Xiangqun directly holds 15.44% and indirectly holds 1.17%; Senior Vice President Gong Huanzhang directly holds 8.10% and indirectly holds 4.11%.

Chen Lei, Li Xiangqun, and Gong Huanzhang are co-founders of Zhongsheng Quantai, collectively controlling 50.87% of the shares, making them the actual controllers.

According to the official website, Zhongsheng Quantai completed Series A financing of 100 million yuan in December 2019, Series A+ financing of 220 million yuan in April 2021, and nearly 100 million yuan in Series B financing by July 2025. Currently, Zhongsheng Quantai has received R&D cooperation orders from companies such as Novartis, Eli Lilly, AstraZeneca, Jiudian Pharmaceutical, and Kangle Pharmaceutical.

Since its establishment, the company has invested approximately 380 million yuan in R&D, and over the next three years, it plans to invest 600 million yuan in R&D.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes